CA2996535A1 - Bacteria engineered to treat disorders involving propionate catabolism - Google Patents

Bacteria engineered to treat disorders involving propionate catabolism Download PDF

Info

Publication number
CA2996535A1
CA2996535A1 CA2996535A CA2996535A CA2996535A1 CA 2996535 A1 CA2996535 A1 CA 2996535A1 CA 2996535 A CA2996535 A CA 2996535A CA 2996535 A CA2996535 A CA 2996535A CA 2996535 A1 CA2996535 A1 CA 2996535A1
Authority
CA
Canada
Prior art keywords
propionate
bacterium
gene
encoding
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2996535A
Other languages
English (en)
French (fr)
Inventor
Dean Falb
Paul Miller
Alex TUCKER
Jonathan Kotula
Vincent ISABELLA
Yves Millet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Operating Co Inc
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/en
Priority claimed from PCT/US2016/037098 external-priority patent/WO2016201380A1/en
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of CA2996535A1 publication Critical patent/CA2996535A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2996535A 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism Abandoned CA2996535A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562199445P 2015-07-31 2015-07-31
US62/199,445 2015-07-31
US201662336338P 2016-05-13 2016-05-13
USPCT/US2016/032565 2016-05-13
US62/336,338 2016-05-13
PCT/US2016/032565 WO2016183532A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to treat a disease or disorder
US201662341320P 2016-05-25 2016-05-25
US62/341,320 2016-05-25
PCT/US2016/037098 WO2016201380A1 (en) 2015-06-10 2016-06-10 Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
USPCT/US2016/037098 2016-06-10
PCT/US2016/044922 WO2017023818A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Publications (1)

Publication Number Publication Date
CA2996535A1 true CA2996535A1 (en) 2017-02-09

Family

ID=57944027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2996535A Abandoned CA2996535A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Country Status (5)

Country Link
EP (1) EP3328988A1 (https=)
JP (1) JP2018521674A (https=)
AU (1) AU2016303662A1 (https=)
CA (1) CA2996535A1 (https=)
WO (1) WO2017023818A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265730A1 (en) * 2019-11-05 2022-08-25 The Trustees Of Columbia University In The City Of New York Engineered Bacteria Containing Biosensors for Precision Targeting and Containment

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7460531B2 (ja) 2017-12-05 2024-04-02 バイオピーエルエックス，インコーポレイティド 微生物感染を防ぐための方法および組成物
AU2020288624B2 (en) 2019-06-04 2025-09-25 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN112143689B (zh) * 2019-06-28 2023-01-03 中国科学院微生物研究所 重组恶臭假单胞菌株的构建及其在转化苏氨酸合成丙酸中的应用
CA3162277A1 (en) * 2019-12-02 2021-06-10 Astellas Pharma Inc. Ny-eso-1-containing artificial adjuvant vector cell for use in treating of cancer
AU2021208600A1 (en) * 2020-01-17 2022-07-28 Université Catholique de Louvain Genetically modified bacterium with altered envelop integrity and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (en) 1998-12-02 2003-03-26 Univ Boston GEN NETWORKS FOR CONTROLLING GENE EXPRESSION
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
CN104024430A (zh) * 2011-08-26 2014-09-03 微生物诊断有限责任公司 用于诊断和治疗心脏缺陷的方法
US20150246085A1 (en) * 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
EP2964240B1 (en) 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265730A1 (en) * 2019-11-05 2022-08-25 The Trustees Of Columbia University In The City Of New York Engineered Bacteria Containing Biosensors for Precision Targeting and Containment

Also Published As

Publication number Publication date
WO2017023818A1 (en) 2017-02-09
JP2018521674A (ja) 2018-08-09
EP3328988A1 (en) 2018-06-06
AU2016303662A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
US12409195B2 (en) Bacteria engineered to reduce hyperphenylalaninemia
US20220233609A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
US20240076645A1 (en) Bacteria engineered to reduce hyperphenylalaninemia
US20170216370A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
US20170253862A1 (en) Bacteria Engineered to Treat Diseases Associated with Hyperammonemia
JP2018523978A (ja) 高アンモニア血症に関連する疾患を治療するために操作された細菌
WO2017075485A1 (en) Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
CA2996535A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
CA3167754A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210721

FZDE Discontinued

Effective date: 20240115